IRIS
CIPRIANI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.900
EU - Europa 8.197
AS - Asia 7.489
SA - Sud America 811
Continente sconosciuto - Info sul continente non disponibili 370
AF - Africa 115
OC - Oceania 27
Totale 32.909
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.483
SG - Singapore 3.312
IT - Italia 1.920
IE - Irlanda 1.632
RU - Federazione Russa 1.547
CN - Cina 1.530
HK - Hong Kong 759
TR - Turchia 721
BR - Brasile 679
VN - Vietnam 630
SE - Svezia 614
DE - Germania 601
GB - Regno Unito 425
UA - Ucraina 410
FR - Francia 361
FI - Finlandia 239
CA - Canada 238
NL - Olanda 160
IN - India 125
BD - Bangladesh 95
JP - Giappone 83
BE - Belgio 46
LT - Lituania 46
ES - Italia 43
MX - Messico 43
ZA - Sudafrica 43
AR - Argentina 42
PL - Polonia 34
ID - Indonesia 29
CZ - Repubblica Ceca 22
EC - Ecuador 21
IQ - Iraq 20
CO - Colombia 19
JM - Giamaica 19
PK - Pakistan 19
CR - Costa Rica 18
VE - Venezuela 18
AU - Australia 17
GT - Guatemala 17
PH - Filippine 17
KR - Corea 15
MA - Marocco 15
SA - Arabia Saudita 15
AT - Austria 14
EU - Europa 14
IL - Israele 14
HN - Honduras 13
JO - Giordania 13
NI - Nicaragua 13
TT - Trinidad e Tobago 13
MY - Malesia 11
RO - Romania 11
CL - Cile 10
DZ - Algeria 10
GR - Grecia 10
NP - Nepal 10
TN - Tunisia 10
UZ - Uzbekistan 10
PR - Porto Rico 9
EE - Estonia 8
NZ - Nuova Zelanda 8
PY - Paraguay 8
SV - El Salvador 8
AL - Albania 7
AZ - Azerbaigian 7
CH - Svizzera 7
EG - Egitto 7
KZ - Kazakistan 7
AE - Emirati Arabi Uniti 6
BB - Barbados 6
BO - Bolivia 6
CW - ???statistics.table.value.countryCode.CW??? 6
HU - Ungheria 6
MK - Macedonia 6
SC - Seychelles 6
TH - Thailandia 6
GP - Guadalupe 5
KE - Kenya 5
LB - Libano 5
PE - Perù 5
TW - Taiwan 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
IR - Iran 4
PT - Portogallo 4
CI - Costa d'Avorio 3
GE - Georgia 3
HR - Croazia 3
KW - Kuwait 3
LU - Lussemburgo 3
MM - Myanmar 3
PS - Palestinian Territory 3
RS - Serbia 3
SN - Senegal 3
UY - Uruguay 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BS - Bahamas 2
ET - Etiopia 2
Totale 32.523
Salva come PNG Salva come JPEG
Città #
Singapore 1.783
San Jose 1.728
Jacksonville 1.643
Dublin 1.625
Chandler 1.609
Ashburn 1.272
Dallas 1.216
Council Bluffs 864
Hong Kong 747
Santa Clara 719
Boardman 579
Izmir 404
New York 370
The Dalles 336
Milan 324
Moscow 294
Nanjing 273
Wilmington 250
Beijing 237
Princeton 236
Lawrence 235
San Mateo 225
Los Angeles 210
Ho Chi Minh City 205
Ann Arbor 196
Rome 155
Lauterbourg 152
Hanoi 129
L'aquila 129
Amsterdam 123
Nanchang 100
Hefei 89
Dearborn 86
Woodbridge 86
São Paulo 85
Munich 81
Seattle 80
Tokyo 74
Naples 69
Shenyang 65
Verona 64
Phoenix 60
Helsinki 57
Des Moines 56
Montreal 55
Shanghai 52
Columbus 51
Orem 50
Chicago 49
Miano 49
Frankfurt am Main 48
L’Aquila 48
Kunming 46
Atlanta 44
Brooklyn 43
Mountain View 43
Brussels 42
Hebei 42
Philadelphia 42
Jiaxing 41
Houston 38
Jinan 35
Toronto 35
Dong Ket 34
Bologna 33
Tianjin 33
Las Vegas 32
Changsha 31
Johannesburg 31
Lappeenranta 30
Norwalk 30
Stockholm 30
San Francisco 29
Zhengzhou 29
Bari 28
Haiphong 27
Denver 26
Turin 26
Chennai 25
London 25
Pescara 25
Pune 25
Warsaw 25
Da Nang 24
Florence 24
Buffalo 23
Vilnius 23
Guangzhou 21
Hangzhou 21
Manchester 21
Genoa 20
New Delhi 20
Palermo 20
Rio de Janeiro 20
Washington 20
Boston 19
Charlotte 19
Brno 18
Ningbo 18
North Bergen 18
Totale 21.096
Salva come PNG Salva come JPEG
Nome #
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 221
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 196
Aumento dei linfociti circolanti gamma-delta Vdelta1+ in corso di malattie infiammatorie intestinali 194
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis 188
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 173
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 173
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 172
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 170
Evaluating the multivisceral involvement on adult-onset Still’s disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study 170
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 169
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 169
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 167
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 167
Prognostic factors of adult onset Still’s disease: analysis of 100 cases in 3 tertiary referral centers 166
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 164
Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis 161
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 161
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. 159
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 158
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 155
Linfociti T Gamma-Delta (G/D) in pazienti con malattie infiammatorie intestinali (IBD) 154
Cardiovascular disease in primary sjögren’s syndrome 154
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort 152
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 152
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 152
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 151
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 151
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 151
Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization 149
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosi 149
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. 149
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences 147
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? 147
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 145
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 145
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 144
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 143
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 143
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis 143
Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort 142
Comment on 'Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?' 141
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 140
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 140
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 140
Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease 139
Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. 138
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 138
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 138
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 137
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 137
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 137
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 136
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis 136
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 136
Endothelial progenitor cells: Are they displaying a function in autoimmune disorders? 136
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 136
Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification 136
Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis 135
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 135
Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor 135
Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms 133
Parenchymal lung disease in adult onset Still's disease: An emergent marker of disease severity - Characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients 133
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 132
The Systemic Score May Identify Life‐Threatening Evolution in Still Disease: Data from the GIRRCS AOSD‐Study Group and the AIDA Network Still Disease Registry 132
Stem cell therapies for systemic sclerosis 132
GAMMA/DELTA T CELL APOPTOSIS IN SYSTEMIC SCLEROSIS PATIENTS 132
Long-term Safety of Rituximab in Primary Sjögren Syndrome: The Experience of a Single Center 131
DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. 131
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 131
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 131
Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. 130
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 130
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 129
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis 128
Combined approach to the initial stage raynaud’s phenomenon diagnosis by means of dynamic digital telehermograpy, capillaroscopy and pletismography. Preliminary findings. 128
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 128
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 128
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 128
Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander? 128
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 127
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 127
Advanced diagnostic imaging and intervention in tendon diseases 127
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 127
The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational "real-life" study 126
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 126
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. 126
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 125
 T cells in placenta and skin: their different functions may support the paradigm of microchimerism in systemic sclerosi 125
Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis 125
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 125
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. 125
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 124
Gamma-delta T cells are not involved in the natural and antibody-dependent cytotoxicity of peripheral blood mononuclear cells in inflammatory bowel disease. 124
Diminished expression of the ubiquitin-proteasome system in early treatment-naïve patients with rheumatoid arthritis and concomitant type 2 diabetes may be linked to IL-1 pathway hyper-activity; results from PEAC cohort 123
Variations of neuronal nitric oxide synthase in systemic sclerosis skin 123
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 123
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis 123
Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. 122
The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still’s disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles 121
Differential expression of SDF-1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis: pathogenetic implication. 121
Totale 14.252
Salva come PNG Salva come JPEG
Categoria #
all - tutte 141.563
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.563
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022899 0 0 0 96 33 19 28 63 108 68 93 391
2022/20234.607 336 251 82 479 395 489 31 298 2.013 30 143 60
2023/20241.248 168 74 82 157 106 363 25 73 9 57 36 98
2024/20255.119 114 89 484 180 650 461 673 394 1.179 213 346 336
2025/202610.275 535 1.005 748 1.149 942 740 1.757 413 1.022 1.130 673 161
2026/20274.027 387 395 899 2.346 0 0 0 0 0 0 0 0
Totale 32.909